through a unique cancer treatment approach, cyteir therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.
Company profile
Ticker
CYT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
455429901
CYT stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
29 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 24
AW
Withdrawal of amendment
21 Mar 24
AW
Withdrawal of amendment
21 Mar 24
AW
Withdrawal of amendment
21 Mar 24
8-K
Termination of a Material Definitive Agreement
20 Mar 24
POS AM
Prospectus update (post-effective amendment)
18 Mar 24
POS AM
Prospectus update (post-effective amendment)
18 Mar 24
Transcripts
Latest ownership filings
4
Braden Michael Leonard
25 Mar 24
SC 13G/A
BML Investment Partners, L.P.
19 Mar 24
4
Braden Michael Leonard
19 Mar 24
3
Braden Michael Leonard
19 Mar 24
SC 13D/A
GAMCO INVESTORS, INC. ET AL
12 Mar 24
4
David G Gaiero
5 Mar 24
4
MARKUS MD RENSCHLER
5 Mar 24
4
Jean George
16 Feb 24
SC 13G/A
Lightstone Ventures II, L.P.
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 129.24 mm | 129.24 mm | 129.24 mm | 129.24 mm | 129.24 mm | 129.24 mm |
Cash burn (monthly) | 1.46 mm | 2.05 mm | 1.72 mm | 3.19 mm | 1.52 mm | 2.15 mm |
Cash used (since last report) | 9.97 mm | 13.98 mm | 11.73 mm | 21.70 mm | 10.34 mm | 14.63 mm |
Cash remaining | 119.27 mm | 115.26 mm | 117.51 mm | 107.54 mm | 118.90 mm | 114.61 mm |
Runway (months of cash) | 81.5 | 56.1 | 68.2 | 33.7 | 78.3 | 53.3 |
Institutional ownership, Q2 2022
68.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 48 |
Opened positions | 15 |
Closed positions | 21 |
Increased positions | 8 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 84.93 mm |
Total shares | 24.73 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Novo Holdings A/S | 4.84 mm | $14.47 mm |
FMR | 3.87 mm | $11.58 mm |
Venrock Associates VII | 3.26 mm | $0.00 |
Baker Bros. Advisors | 2.64 mm | $7.90 mm |
Osage University GP II | 2.47 mm | $28.14 mm |
OUP Management | 2.47 mm | $7.40 mm |
Avidity Partners Management | 1.85 mm | $5.53 mm |
Vanguard | 611.60 k | $1.83 mm |
Newtyn Management | 606.25 k | $1.81 mm |
Laurion Capital Management | 359.50 k | $1.08 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Mar 24 | Braden Michael Leonard | Common Stock, par value $0.001 per share | Buy | Acquire P | Yes | No | 2.95 | 170,589 | 503.24 k | 3,654,053 |
18 Mar 24 | Braden Michael Leonard | Common Stock, par value $0.001 per share | Buy | Acquire P | Yes | No | 3.01 | 113,777 | 342.47 k | 3,483,464 |
4 Mar 24 | Markus MD Renschler | Common Stock | Option exercise | Acquire M | No | No | 1.69 | 6,304 | 10.65 k | 1,103,661 |
4 Mar 24 | Markus MD Renschler | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.69 | 6,304 | 10.65 k | 220,648 |
4 Mar 24 | David G Gaiero | Common Stock | Option exercise | Acquire M | No | No | 1.69 | 2,373 | 4.01 k | 102,391 |
4 Mar 24 | David G Gaiero | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.69 | 2,373 | 4.01 k | 83,052 |
29 Feb 24 | Markus MD Renschler | Common Stock | Option exercise | Acquire M | No | No | 1.2 | 2,537 | 3.04 k | 1,097,357 |
29 Feb 24 | Markus MD Renschler | Common Stock | Option exercise | Acquire M | No | No | 1.69 | 12,607 | 21.31 k | 1,094,820 |
29 Feb 24 | Markus MD Renschler | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.2 | 2,537 | 3.04 k | 0 |
29 Feb 24 | Markus MD Renschler | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.69 | 12,607 | 21.31 k | 226,952 |